Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
In October last year, the stock of Korro Bio (KRRO) was riding high at >$50 per share - the RNA editing specialist biotech achieved its Nasdaq listing via an all-stock reverse merger with Frequency ...
Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.
ProQR Therapeutics N.V. (Nasdaq: PRQR) ('ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing ...
RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
BEIJING -- A Chinese research team has achieved a breakthrough with its newly developed RNA editing technology, named LEAPER, in the treatment of Duchenne muscular dystrophy (DMD), a severe and rare ...
Researchers have spent decades—and billions of dollars—sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining ...
The firm will use the proceeds to advance its pipeline of RNA medicines, like AX-0810 and AX-0811, and its Axiomer RNA-editing platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results